Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 395

1.

Caregiver burden and health-related quality of life in idiopathic dystonia patients under botulinum toxin treatment: a cross-sectional study.

Drexel SC, Klietz M, Kollewe K, Paracka L, Kutschenko A, Kopp B, Lange F, Wegner F, Dressler D.

J Neural Transm (Vienna). 2020 Jan;127(1):61-70. doi: 10.1007/s00702-019-02109-6. Epub 2019 Dec 4.

2.

OnabotulinumtoxinA should be considered in medication overuse withdrawal in patients with chronic migraine.

Dressler D.

Brain. 2020 Jan 1;143(1):e5. doi: 10.1093/brain/awz366. No abstract available.

PMID:
31782764
3.

Comparing lanbotulinumtoxinA (Hengli®) with onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®) in the mouse hemidiaphragm assay.

Pan L, Bigalke H, Kopp B, Jin L, Dressler D.

J Neural Transm (Vienna). 2019 Dec;126(12):1625-1629. doi: 10.1007/s00702-019-02100-1. Epub 2019 Nov 9.

PMID:
31707463
4.

More than hemifacial spasm? A case of unilateral facial spasms with systematic review of red flags.

Sringean J, Dressler D, Bhidayasiri R.

J Neurol Sci. 2019 Dec 15;407:116532. doi: 10.1016/j.jns.2019.116532. Epub 2019 Oct 13.

PMID:
31683060
5.

Advance Directives of German People with Parkinson's Disease Are Unspecific in regard to Typical Complications.

Klietz M, Öcalan Ö, Schneider N, Dressler D, Stiel S, Wegner F.

Parkinsons Dis. 2019 Aug 4;2019:2107821. doi: 10.1155/2019/2107821. eCollection 2019.

6.

Altered Neurometabolic Profile in Early Parkinson's Disease: A Study With Short Echo-Time Whole Brain MR Spectroscopic Imaging.

Klietz M, Bronzlik P, Nösel P, Wegner F, Dressler DW, Dadak M, Maudsley AA, Sheriff S, Lanfermann H, Ding XQ.

Front Neurol. 2019 Jul 17;10:777. doi: 10.3389/fneur.2019.00777. eCollection 2019.

7.

IncobotulinumtoxinA for hypersalivation in patients with amyotrophic lateral sclerosis: an open-label single-centre study.

Paracka L, Kollewe K, Klietz M, Petri S, Dressler D.

J Neural Transm (Vienna). 2019 Oct;126(10):1341-1345. doi: 10.1007/s00702-019-02044-6. Epub 2019 Jul 17.

PMID:
31317261
8.

Botulinum toxin type D blocks autonomic cholinergic synapses in humans: discussion of a potential therapeutic use.

Dressler D, Kollewe K, Kruger THC, Gade N, Sikorra S, Bigalke H.

J Neural Transm (Vienna). 2019 Oct;126(10):1337-1340. doi: 10.1007/s00702-019-02029-5. Epub 2019 Jun 15.

PMID:
31203435
9.

Do complexing proteins provide mechanical protection for botulinum neurotoxins?

Dressler D, Pan L, Adib Saberi F, Bigalke H.

J Neural Transm (Vienna). 2019 Aug;126(8):1047-1050. doi: 10.1007/s00702-019-02023-x. Epub 2019 Jun 6.

PMID:
31168666
10.

A hexanucleotide repeat modifies expressivity of X-linked dystonia parkinsonism.

Westenberger A, Reyes CJ, Saranza G, Dobricic V, Hanssen H, Domingo A, Laabs BH, Schaake S, Pozojevic J, Rakovic A, Grütz K, Begemann K, Walter U, Dressler D, Bauer P, Rolfs A, Münchau A, Kaiser FJ, Ozelius LJ, Jamora RD, Rosales RL, Diesta CCE, Lohmann K, König IR, Brüggemann N, Klein C.

Ann Neurol. 2019 Jun;85(6):812-822. doi: 10.1002/ana.25488. Epub 2019 May 3.

PMID:
30973967
11.

Validating the Parkinson's disease caregiver burden questionnaire (PDCB) in German caregivers of advanced Parkinson's disease patients.

Klietz M, Rippena L, Lange F, Tulke A, Paracka L, Dressler D, Wegner F.

Int Psychogeriatr. 2019 Dec;31(12):1791-1800. doi: 10.1017/S1041610219000206. Epub 2019 Mar 25.

PMID:
30907331
12.

Botulinum neurotoxin a therapy efficacy and safety for oromandibular dystonia: a meta-analysis.

Dadgardoust PD, Rosales RL, Asuncion RM, Dressler D.

J Neural Transm (Vienna). 2019 Feb;126(2):141-148. doi: 10.1007/s00702-018-1960-7. Epub 2019 Jan 2.

PMID:
30604200
13.

[Treatment goals in patients with post-stroke upper limb spasticity following injection of botulinum toxin A : Results of the German-Austrian subgroup of the ULIS-II study].

Fheodoroff K, Dressler D, Woldag H, Koßmehl P, Koch M, Maisonobe P, Reichel G.

Nervenarzt. 2019 Apr;90(4):361-370. doi: 10.1007/s00115-018-0630-1. German.

PMID:
30324541
14.

Antibody-induced failure of botulinum toxin therapy: re-start with low-antigenicity drugs offers a new treatment opportunity.

Dressler D, Pan L, Adib Saberi F.

J Neural Transm (Vienna). 2018 Oct;125(10):1481-1486. doi: 10.1007/s00702-018-1911-3. Epub 2018 Jul 31.

PMID:
30066275
15.

Botulinum toxin therapy of hemifacial spasm: bilateral injections can reduce facial asymmetry.

Xiao L, Pan L, Li B, Zhou Y, Pan Y, Zhang X, Hu Y, Dressler D, Jin L.

J Neurol. 2018 Sep;265(9):2097-2105. doi: 10.1007/s00415-018-8960-2. Epub 2018 Jul 9.

PMID:
29987587
16.

Comparing incobotulinumtoxinA (Xeomin®) and onabotulinumtoxinA (Botox®): identical potency labelling in the hemidiaphragm assay.

Dressler D, Pan L, Bigalke H.

J Neural Transm (Vienna). 2018 Sep;125(9):1351-1354. doi: 10.1007/s00702-018-1897-x. Epub 2018 Jun 26.

PMID:
29946929
17.

A novel helmet-mounted device for reducing the potential of catastrophic cervical spine fractures and spinal cord injuries in head-first impacts.

Dressler DM, Dennison CR, Whyte T, Cripton PA.

Clin Biomech (Bristol, Avon). 2019 Apr;64:22-27. doi: 10.1016/j.clinbiomech.2018.04.014. Epub 2018 Apr 26.

PMID:
29724412
18.

Impaired Quality of Life and Need for Palliative Care in a German Cohort of Advanced Parkinson's Disease Patients.

Klietz M, Tulke A, Müschen LH, Paracka L, Schrader C, Dressler DW, Wegner F.

Front Neurol. 2018 Mar 6;9:120. doi: 10.3389/fneur.2018.00120. eCollection 2018.

19.

Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy.

Dressler D, Bhidayasiri R, Bohlega S, Chana P, Chien HF, Chung TM, Colosimo C, Ebke M, Fedoroff K, Frank B, Kaji R, Kanovsky P, Koçer S, Micheli F, Orlova O, Paus S, Pirtosek Z, Relja M, Rosales RL, Sagástegui-Rodríguez JA, Schoenle PW, Shahidi GA, Timerbaeva S, Walter U, Saberi FA.

J Neurol. 2018 Apr;265(4):856-862. doi: 10.1007/s00415-018-8759-1. Epub 2018 Feb 8.

PMID:
29423615
20.

Stat3 and CCAAT enhancer-binding protein β (C/ebpβ) activate Fanconi C gene transcription during emergency granulopoiesis.

Shah CA, Broglie L, Hu L, Bei L, Huang W, Dressler DB, Eklund EA.

J Biol Chem. 2018 Mar 16;293(11):3937-3948. doi: 10.1074/jbc.RA117.000528. Epub 2018 Jan 30.

21.

Botulinum toxin therapy in patients with oral anticoagulation: is it safe?

Schrader C, Ebke M, Adib Saberi F, Dressler D.

J Neural Transm (Vienna). 2018 Feb;125(2):173-176. doi: 10.1007/s00702-017-1809-5. Epub 2017 Nov 7.

PMID:
29116410
22.

Sensory Alterations in Patients with Isolated Idiopathic Dystonia: An Exploratory Quantitative Sensory Testing Analysis.

Paracka L, Wegner F, Blahak C, Abdallat M, Saryyeva A, Dressler D, Karst M, Krauss JK.

Front Neurol. 2017 Oct 17;8:553. doi: 10.3389/fneur.2017.00553. eCollection 2017.

23.

Efficiently finding and using evidence to guide clinical practice and improve care.

Akbashev MY, Pittman JR, Dressler DD.

JAAPA. 2017 Nov;30(11):31-38. doi: 10.1097/01.JAA.0000525915.05473.01. Review.

PMID:
29064936
24.

Identification of Shiga-Toxigenic Escherichia coli outbreak isolates by a novel data analysis tool after matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

Christner M, Dressler D, Andrian M, Reule C, Petrini O.

PLoS One. 2017 Sep 6;12(9):e0182962. doi: 10.1371/journal.pone.0182962. eCollection 2017.

25.

Long-term stability of reconstituted incobotulinumtoxinA: how can we reduce costs of botulinum toxin therapy?

Dressler D, Bigalke H.

J Neural Transm (Vienna). 2017 Oct;124(10):1223-1225. doi: 10.1007/s00702-017-1767-y. Epub 2017 Aug 2. Review.

PMID:
28770389
26.

Strategies to decrease injection site pain in botulinum toxin therapy.

Paracka L, Kollewe K, Wegner F, Dressler D.

J Neural Transm (Vienna). 2017 Oct;124(10):1213-1216. doi: 10.1007/s00702-017-1764-1. Epub 2017 Jul 24.

PMID:
28741118
27.

A brief history of neurological botulinum toxin therapy in Germany.

Dressler D, Roggenkaemper P.

J Neural Transm (Vienna). 2017 Oct;124(10):1217-1221. doi: 10.1007/s00702-017-1762-3. Epub 2017 Jul 21. Review.

PMID:
28733711
28.

Effects of levodopa/carbidopa intestinal gel versus oral levodopa/carbidopa on B vitamin levels and neuropathy.

Loens S, Chorbadzhieva E, Kleimann A, Dressler D, Schrader C.

Brain Behav. 2017 Apr 7;7(5):e00698. doi: 10.1002/brb3.698. eCollection 2017 May.

29.

Economics of botulinum toxin therapy: influence of the abobotulinumtoxinA package size on the costs of botulinum toxin therapy.

Dressler D, Adib Saberi F.

J Clin Mov Disord. 2017 Apr 27;4:6. doi: 10.1186/s40734-017-0049-z. eCollection 2017.

30.

Botulinum toxin in the management of chronic migraine: clinical evidence and experience.

Escher CM, Paracka L, Dressler D, Kollewe K.

Ther Adv Neurol Disord. 2017 Feb;10(2):127-135. doi: 10.1177/1756285616677005. Epub 2016 Nov 16. Review.

31.

Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The TOWER study.

Wissel J, Bensmail D, Ferreira JJ, Molteni F, Satkunam L, Moraleda S, Rekand T, McGuire J, Scheschonka A, Flatau-Baqué B, Simon O, Rochford ET, Dressler D, Simpson DM; TOWER study investigators.

Neurology. 2017 Apr 4;88(14):1321-1328. doi: 10.1212/WNL.0000000000003789. Epub 2017 Mar 10.

32.

Dopaminergic modulation of performance monitoring in Parkinson's disease: An event-related potential study.

Seer C, Lange F, Loens S, Wegner F, Schrader C, Dressler D, Dengler R, Kopp B.

Sci Rep. 2017 Jan 24;7:41222. doi: 10.1038/srep41222.

33.

Sonographic alteration of substantia nigra is related to parkinsonism-predominant course of X-linked dystonia-parkinsonism.

Walter U, Rosales R, Rocco A, Westenberger A, Domingo A, Go CL, Brüggemann N, Klein C, Lee LV, Dressler D.

Parkinsonism Relat Disord. 2017 Apr;37:43-49. doi: 10.1016/j.parkreldis.2017.01.006. Epub 2017 Jan 10.

PMID:
28094105
34.

Immunological aspects of botulinum toxin therapy.

Dressler D, Bigalke H.

Expert Rev Neurother. 2017 May;17(5):487-494. doi: 10.1080/14737175.2017.1262258. Epub 2016 Nov 28. Review.

PMID:
27852103
35.

Impaired heart rate variability in cervical dystonia is associated to depression.

Hentschel F, Dressler D, Abele M, Paus S.

J Neural Transm (Vienna). 2017 Feb;124(2):245-251. doi: 10.1007/s00702-016-1639-x. Epub 2016 Nov 5.

PMID:
27816992
36.

Frontalis suspension surgery to treat patients with blepharospasm and eyelid opening apraxia: long-term results.

Dressler D, Karapantzou C, Rohrbach S, Schneider S, Laskawi R.

J Neural Transm (Vienna). 2017 Feb;124(2):253-257. doi: 10.1007/s00702-016-1641-3. Epub 2016 Nov 5.

PMID:
27816991
37.

Neural mechanisms underlying cognitive inflexibility in Parkinson's disease.

Lange F, Seer C, Loens S, Wegner F, Schrader C, Dressler D, Dengler R, Kopp B.

Neuropsychologia. 2016 Dec;93(Pt A):142-150. doi: 10.1016/j.neuropsychologia.2016.09.021. Epub 2016 Sep 28.

PMID:
27693667
38.

Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force.

Dressler D, Bhidayasiri R, Bohlega S, Chahidi A, Chung TM, Ebke M, Jacinto LJ, Kaji R, Koçer S, Kanovsky P, Micheli F, Orlova O, Paus S, Pirtosek Z, Relja M, Rosales RL, Sagástegui-Rodríguez JA, Schoenle PW, Shahidi GA, Timerbaeva S, Walter U, Saberi FA.

J Neurol. 2017 Jan;264(1):112-120. doi: 10.1007/s00415-016-8304-z. Epub 2016 Oct 27. Review.

PMID:
27787630
39.

Safety of botulinum toxin short interval therapy using incobotulinumtoxin A.

Dressler D, Saberi FA.

J Neural Transm (Vienna). 2017 Apr;124(4):437-440. doi: 10.1007/s00702-016-1628-0. Epub 2016 Oct 17.

PMID:
27747444
40.

Dopamine DRD2 polymorphism (DRD2/ANNK1-Taq1A) is not a significant risk factor in writer's cramp.

Zeuner KE, Acewicz A, Knutzen A, Dressler D, Lohmann K, Witt K.

J Neurogenet. 2016 Sep - Dec;30(3-4):276-279. Epub 2016 Oct 4.

PMID:
27696930
41.

Erratum to: 'Quality of life and costs of spasticity treatment in German stroke patients'.

Rychlik R, Kreimendahl F, Schnur N, Lambert-Baumann J, Dressler D.

Health Econ Rev. 2016 Dec;6(1):41. doi: 10.1186/s13561-016-0114-6. Epub 2016 Aug 31. No abstract available.

42.

Quality of life and costs of spasticity treatment in German stroke patients.

Rychlik R, Kreimendahl F, Schnur N, Lambert-Baumann J, Dressler D.

Health Econ Rev. 2016 Dec;6(1):27. doi: 10.1186/s13561-016-0107-5. Epub 2016 Jul 8. Erratum in: Health Econ Rev. 2016 Dec;6(1):41.

43.

Meta-analytical and electrophysiological evidence for executive dysfunction in primary dystonia.

Lange F, Seer C, Salchow C, Dengler R, Dressler D, Kopp B.

Cortex. 2016 Sep;82:133-146. doi: 10.1016/j.cortex.2016.05.018. Epub 2016 Jun 8.

PMID:
27376933
44.

Cognitive Flexibility in Primary Dystonia.

Lange F, Seer C, Dengler R, Dressler D, Kopp B.

J Int Neuropsychol Soc. 2016 Jul;22(6):662-70. doi: 10.1017/S135561771600045X.

PMID:
27333537
45.

Chronic hip pain. Gelatinous marrow transformation (bone marrow starvation syndrome).

Dressler D, Shepel M, Obaid H.

Skeletal Radiol. 2016 Sep;45(9):1291-2. 1317-8. doi: 10.1007/s00256-016-2396-5. No abstract available.

PMID:
27105619
46.

Reconstituting botulinum toxin drugs: shaking, stirring or what?

Dressler D, Bigalke H.

J Neural Transm (Vienna). 2016 May;123(5):523-5. doi: 10.1007/s00702-016-1538-1. Epub 2016 Apr 21.

PMID:
27100914
47.

Long-term treatment of chronic migraine with OnabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting.

Kollewe K, Escher CM, Wulff DU, Fathi D, Paracka L, Mohammadi B, Karst M, Dressler D.

J Neural Transm (Vienna). 2016 May;123(5):533-40. doi: 10.1007/s00702-016-1539-0. Epub 2016 Mar 31.

PMID:
27032774
48.

Botulinum toxin therapy: reduction of injection site pain by pH normalisation.

Dressler D, Adib Saberi F, Bigalke H.

J Neural Transm (Vienna). 2016 May;123(5):527-31. doi: 10.1007/s00702-016-1522-9. Epub 2016 Mar 22.

PMID:
27002815
49.

Evidence of TAF1 dysfunction in peripheral models of X-linked dystonia-parkinsonism.

Domingo A, Amar D, Grütz K, Lee LV, Rosales R, Brüggemann N, Jamora RD, Cutiongco-Dela Paz E, Rolfs A, Dressler D, Walter U, Krainc D, Lohmann K, Shamir R, Klein C, Westenberger A.

Cell Mol Life Sci. 2016 Aug;73(16):3205-15. doi: 10.1007/s00018-016-2159-4. Epub 2016 Feb 15.

PMID:
26879577
50.

Long-term efficacy and safety of incobotulinumtoxinA and conventional treatment of poststroke arm spasticity: a prospective, non-interventional, open-label, parallel-group study.

Dressler D, Rychlik R, Kreimendahl F, Schnur N, Lambert-Baumann J.

BMJ Open. 2015 Dec 30;5(12):e009358. doi: 10.1136/bmjopen-2015-009358.

Supplemental Content

Loading ...
Support Center